Streetwise Reports

The Gold Report

The Energy Report

The Life Sciences Report

Research Reports

Streetwise Reports

The Gold Report

The Energy Report

The Life Sciences Report

Research Reports

Trending Now

Co. Reports Positive Results in Phase 2b/3 Alzheimer's Trial

Streetwise Reports (12/05/2022)

Co. Reports Positive Results in Phase 2b/3 Alzheimer's Trial

Shares of Anavex Life Sciences Corp. traded 36% higher Friday after the company reported that during a Phase 2b/3 clinical trial of patients diagnosed with early Alzheimer's disease, its ANAVEX®2-73 (blarcamesine) met both key primary and secondary endpoints and demonstrated significant reductions in clinical decline.

Tags: Biotechnology / Pharmaceuticals

Target Price Boosted on Canadian Pharma Co.

Research Report

Dr. Andre Uddin (11/30/2022)

Target Price Boosted on Canadian Pharma Co.

This company, undergoing a business model shift, is doing well and remains Buy rated despite a weaker-than-expected Q3/22, noted a Research Capital Corp. report.

Tags: Biotechnology / Pharmaceuticals

Expert Says Health Tech Co. Is in Another Buy Spot

Contributed Opinion

Clive Maund (11/30/2022)

Expert Says Health Tech Co. Is in Another Buy Spot

Expert Clive Maund reviews the 1-year chart for Reliq Health Technologies to tell you why he believes it is in another buy spot.

Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

Biopharma Co. Now at a Bargain Price, Analyst Says

Research Report

Dr. Andrew Uddin (11/29/2022)

Biopharma Co. Now at a Bargain Price, Analyst Says

Recent share price weakness and a catalyst-rich next six months are good news for investors, noted a Research Capital Corp. report.

Tags: Biotechnology / Pharmaceuticals

Major Contract and Faster Commercialization for Chemicals Co.

Contributed Opinion

Penny Queen (11/29/2022)

Major Contract and Faster Commercialization for Chemicals Co.

Since hitting the market on November 10, 2022, ASP Isotopes has been busy and has now announced a US$675 million-dollar contract. Expert Penny Queen shares this news and reviews why she still believes this company is worthwhile.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Trades to New 52-Week High

Streetwise Reports (11/28/2022)

Biopharma Co. Trades to New 52-Week High

Shares of Axsome Therapeutics Inc. traded to a new 52-week high after the company reported its AXS-05 successfully met both the primary and key secondary endpoints in the Phase 3 ACCORD Alzheimer's disease agitation trial.

Tags: Biotechnology / Pharmaceuticals

Expert Says Health Tech Co. Still in Good Spot To Buy

Contributed Opinion

Clive Maund (11/28/2022)

Expert Says Health Tech Co. Still in Good Spot To Buy

Technical analyst Clive Maund reviews the 1-year chart for Reliq Health Technologies to tell you whether he believes it is a Buy.

Tags: Life Sciences Tools & DiagnosticsTechnology

Pharma Co. Gains Approval for SARS-CoV-2 Drug

Streetwise Reports (11/23/2022)

Pharma Co. Gains Approval for SARS-CoV-2 Drug

Shares of Japanese pharmaceutical firm Shionogi & Co. Ltd. traded nearly 13% higher yesterday after the company reported it received emergency regulatory approval from Japan's Ministry of Health, Labor, and Welfare for its Xocova® (ensitrelvir fumaric acid) tablets for use in treating SARS-CoV-2 infection.

Tags: Biotechnology / Pharmaceuticals

Life Sciences Co. Exceeds Expectations in Q3/22

Research Report

Dr. Andre Uddin (11/22/2022)

Life Sciences Co. Exceeds Expectations in Q3/22

During the quarter, the Canadian specialty biopharma performed well and maintained a healthy balance sheet, such that it raised revenue guidance for this year, noted a Research Capital Corp. report.

Tags: Biotechnology / Pharmaceuticals

Blockchain Co. Signs Agreement With Insurance Co.

Streetwise Reports (11/22/2022)

Blockchain Co. Signs Agreement With Insurance Co.

Global Compliance Applications Corp. signs an agreement with a South African insurance company to get into that country’s expanding cannabis industry.

Tags: CannabisTechnologyCryptocurrency / Blockchain

Q4/22 Catalysts Could Boost Undervalued Biopharma Stock

Research Report

Dr. Yale Jen (11/22/2022)

Q4/22 Catalysts Could Boost Undervalued Biopharma Stock

The year's final quarter is significant for this U.S.-based firm given the trio of significant clinical achievements in its sight, noted a Laidlaw & Co. report.

Tags: Biotechnology / Pharmaceuticals

Global Drug Co. Offers US$1.35B To Boost Hematology Assets

Streetwise Reports (11/22/2022)

Global Drug Co. Offers US$1.35B To Boost Hematology Assets

Imago BioSciences Inc. shares traded 104.5% higher yesterday to a new 52-week high after the company reported it entered into a definitive agreement to be acquired by Merck & Co. in an all-cash transaction for US$36.00 per share.

Tags: Biotechnology / Pharmaceuticals

FDA Awards Breakthrough Therapy Status for AMD Drug

Streetwise Reports (11/21/2022)

FDA Awards Breakthrough Therapy Status for AMD Drug

Iveric Bio Inc. shares traded 25% higher Friday after the company reported that the U.S. FDA has granted breakthrough therapy designation for its avacincaptad pegol for use in the treatment of geographic atrophy secondary to age-related macular degeneration.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Won't See Bump in Sales From New COVID Drug

Research Report

Dr. Andre Uddin (11/18/2022)

Pharma Co. Won't See Bump in Sales From New COVID Drug

The U.S. Food and Drug Administration Advisory Panel denied the approval of this therapeutic for patients hospitalized with severe SARS-CoV-2, yet it is still a Buy, noted a Research Capital Corp. report.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Hopes To Turn US$30M Into US$2B

Streetwise Reports (11/17/2022)

Biopharma Co. Hopes To Turn US$30M Into US$2B

CytomX Therapeutics Inc. shares traded 32% higher after the company reported it has formed a strategic research collaboration with Regeneron Pharmaceuticals Inc. to develop next-generation bispecific immunotherapies to treat multiple cancer tumor types.

Tags: Biotechnology / Pharmaceuticals

Expert Investing Ideas

"Data presented by peers at the CTAD conference are relevant to PMN."

–Douglas Loe, Leede Jones Gable

"Positive Phase 2a data were achieved with AGN's ifenprodil."

–Dr. André Uddin, Research Capital Corporation

"This is a good point to add to positions or make new purchases of RHQ."

–Clive Maund, CliveMaund.com

"RHT added 50 new nursing home clients in Florida to its network."

–Douglas Loe, Leede Jones Gable

"The dip of recent days presents us with a better entry point for RHT."

–Clive Maund, CliveMaund.com

"PMN expects to file an NDA for PMN310 with the FDA by 2022E."

–Steve Silver, Argus Research

"AGN is rated a Buy again here."

–Clive Maund, CliveMaund.com

"AGN is rated an immediate Strong Buy."

–Clive Maund, CliveMaund.com

"This is a good time to buy PMN stock."

–Clive Maund, CliveMaund.com

"PMN peer, Eisai, reported positive Phase 3 Alzheimer's disease data."

–Douglas Loe, Leede Jones Gable

"We are positive about PMN's PMN-310 possibly mitigating AD progression."

–Douglas Loe, Leede Jones Gable

"A minor relief rally in the broad market could see AGN shoot up again."

–Clive Maund, CliveMaund.com

"The case for buying AGN here could scarcely be stronger."

–Clive Maund, CliveMaund.com

"AGN is rated Buy again here."

–Clive Maund, CliveMaund.com

"AGN has the capacity to make really big moves."

–Clive Maund, CliveMaund.com

"Experiments showed that PMN's PMN310 has a unique binding profile."

–Douglas Loe, Leede Jones Gable

"AGN is considered to be at another good buy spot here."

–Clive Maund, CliveMaund.com

"It would be logical for AGN to develop ifenprodil for two indications."

–Dr. André Uddin, Research Capital Corporation

"In the Phase 2a trial in IPF, AGN's ifenprodil hit its endpoint."

–Dr. André Uddin, Research Capital Corporation

"RHT's quality of net income earnings is extremely high."

–Jefferson Research

Company News

RHT:TSX.V; RQHTF:OTCQB; A2AJTB:WKN
12/6/2022 – Reliq Health Technologies, Inc. Announces 35 New Skilled Nursing Facilities Clients in Florida

AGN:CSE; AGNPF:OTCQB; AGN0:XFRA
12/5/2022 – Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

AWKN:NEO; AWKNF:OTCQB
12/1/2022 – Awakn Life Sciences Announces Signing of Lease for Second Clinic in Norway

RHT:TSX.V; RQHTF:OTCQB; A2AJTB:WKN
11/29/2022 – Reliq Health Technologies, Inc. Files Q1 FY 2023 Financial Statements, Announces Record Growth

Tune In to Our NEW Podcast: Streetwise Listens

NASDAQ Biotech ARCA Pharmaceutical

Biotech Co.'s Shares Rise 38% on Ph. 1/2 Wet AMD Trial Data

Streetwise Reports (11/16/2022)

Biotech Co.'s Shares Rise 38% on Ph. 1/2 Wet AMD Trial Data

4D Molecular Therapeutics Inc. shares traded 38.5% higher yesterday after the company reported interim data from its Phase 1/2 clinical trial of Intravitreal 4D-150 for use in the treatment of wet age-related macular degeneration.

Tags: Biotechnology / Pharmaceuticals

UK Co. Buys NARCAN® Nasal Spray Maker

Streetwise Reports (11/14/2022)

UK Co. Buys NARCAN® Nasal Spray Maker

Opiant Pharmaceuticals Inc. shares traded 111% higher after the company reported it entered into a definitive agreement to be acquired by Indivior Plc. for US$20.00 per share in cash. Opiant shareholders will also receive contingent value rights that are worth up to an additional US$8.00/share if certain product sales milestones are met.

Tags: Biotechnology / Pharmaceuticals

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment

Streetwise Reports (11/14/2022)

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment

This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon.

Tags: PsychedelicsBiotechnology / Pharmaceuticals

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

Streetwise Reports (11/11/2022)

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors, according to various analysts.

Tags: Biotechnology / Pharmaceuticals

Biologics Co. Doubles Revenue in Q3/22

Streetwise Reports (11/11/2022)

Biologics Co. Doubles Revenue in Q3/22

ADMA Biologics Inc. shares traded 27.5% higher after the company reported Q3/22 financial results that included a 99% YOY revenue increase. The firm added that it is raising its FY/22 revenue estimates from US$130 million to US$145 million.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Trades 200% Higher

Streetwise Reports (11/10/2022)

Pharma Co. Trades 200% Higher

Merrimack Pharmaceuticals Inc. shares traded 200% higher yesterday to a new 52-week high after the company advised that Ipsen SA reported that in a Phase 3 clinical trial, Onivyde® regimen was shown to significantly improve overall survival in previously untreated patients afflicted with metastatic pancreatic ductal adenocarcinoma.

Tags: Biotechnology / Pharmaceuticals